Zuclopenthixol-induced neuroleptic malignant syndrome at rechallenge and its extrapyramidal effects.
This is the first report of a zuclopenthixol-induced NMS. The lack of previous reports may be because the receptor-binding profile of thioxanthenes give rise to fewer extrapyramidal effects than comparable neuroleptics. It is important to know more of the relationship between the potential for induction of extrapyramidal effects and success in NMS rechallenge.
Kemperman
C J
CJ
Department of Psychiatry, State University Hospital, Groningen, The Netherlands.
D000328:Adult; D003006:Clopenthixol / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy; D013892:Thioxanthenes / Q000009:adverse effects*
D013892:Thioxanthenes; D003006:Clopenthixol